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Background: Nonalcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide. Type 2 dia-
betes mellitus (T2DM) is a risk factor that accelerates NAFLD progression, leading to fibrosis and cirrhosis. Thus, here we aimed to 
develop a simple model to predict the presence of NAFLD based on clinical parameters of patients with T2DM.
Methods: A total of 698 patients with T2DM who visited five medical centers were included. NAFLD was evaluated using transient 
elastography. Univariate logistic regression analyses were performed to identify potential contributors to NAFLD, followed by mul-
tivariable logistic regression analyses to create the final prediction model for NAFLD.
Results: Two NAFLD prediction models were developed, with and without serum biomarker use. The non-laboratory model com-
prised six variables: age, sex, waist circumference, body mass index (BMI), dyslipidemia, and smoking status. For a cutoff value of 
≥60, the prediction accuracy was 0.780 (95% confidence interval [CI], 0.743 to 0.817). The second comprehensive model showed 
an improved discrimination ability of up to 0.815 (95% CI, 0.782 to 0.847) and comprised seven variables: age, sex, waist circum-
ference, BMI, glycated hemoglobin, triglyceride, and alanine aminotransferase to aspartate aminotransferase ratio. Our non-labora-
tory model showed non-inferiority in the prediction of NAFLD versus previously established models, including serum parameters.
Conclusion: The new models are simple and user-friendly screening methods that can identify individuals with T2DM who are at 
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high-risk for NAFLD. Additional studies are warranted to validate these new models as useful predictive tools for NAFLD in clini-
cal practice.
Keywords: Non-alcoholic fatty liver disease; Diabetes mellitus, type 2; Transient elastography; Screening
INTRODUCTION
The prevalence of nonalcoholic fatty liver disease (NAFLD) is 
increasing worldwide, making it one of the most common 
causes of chronic liver disease [1]. NAFLD is defined as an ex-
cessive hepatic fat accumulation of more than 5% in hepato-
cytes without secondary causes such as significant alcohol in-
take, steatogenic medications, or viral hepatitis [2]. NAFLD, a 
heterogeneous disease that covers a wide spectrum of presenta-
tions from simple steatosis to nonalcoholic steatohepatitis 
(NASH), is associated with hepatocyte ballooning that can 
progress to cirrhosis and even hepatocellular carcinoma [2,3]. 
The clinical importance of NAFLD includes its relationship 
with advanced liver diseases and its close association with insu-
lin resistance, type 2 diabetes mellitus (T2DM), obesity, and 
metabolic syndrome, leading to an increased risk of cardiovas-
cular morbidity [3,4].
T2DM is associated with a worse prognosis of NAFLD. In 
T2DM, the estimated prevalence of NAFLD is 55.5%, approxi-
mately two-fold higher than that in the general population [5]. 
Among patients with T2DM and concomitant NAFLD, 37.3% 
have NASH, an advanced form of NAFLD [5]. In addition, 
T2DM accelerates NAFLD progression two-fold compared to 
NAFLD alone [6]. Meanwhile, accumulating evidence shows 
that NAFLD aggravates microvascular and macrovascular com-
plications in T2DM [4,7,8]. Thus, the early detection and inter-
vention of NAFLD are especially important for patients with 
T2DM to reduce morbidity and mortality rates.
Although liver biopsy is the gold standard for assessing 
NAFLD [4], its invasive nature and sampling variability limit 
its routine use. Furthermore, imaging modalities for the diagno-
sis of NAFLD, such as hepatic ultrasound, computed tomogra-
phy (CT), or magnetic resonance imaging (MRI), are expensive, 
inconvenient, and sometimes unavailable in community hospi-
tal-based settings. Therefore, for the timely diagnosis of 
NAFLD, clinical prediction models using various laboratory 
parameters have been developed to screen high-risk patients. 
For example, alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) are the most commonly used laboratory 
parameters in clinical prediction models of NAFLD [4,9]. How-
ever, these models require hospital visits with additional blood 
sampling for the prediction of NAFLD and cannot be easily ap-
plied to patients. Although a non-laboratory-based scoring mod-
el for NAFLD was recently suggested [10], it has not been vali-
dated in patients with T2DM alone.
Thus, we investigated the clinical risk factors associated with 
NAFLD in patients with T2DM and developed a non-laboratory 
parameter-based simple screening model for NAFLD in these 
patients. We also attempted to provide a more comprehensive 
model with superior predictive power for NAFLD using labora-
tory parameters in patients with T2DM. These prediction mod-
els were developed and validated using a combined health 
screening database from five medical centers and liver transient 




This cross-sectional study collected data from five medical cen-
ters (four tertiary hospitals, one secondary hospital) in Korea 
between January 2005 and August 2018: Severance Health 
Check-up Center, Gangnam Severance Hospital, Soonchunhy-
ang University Cheonan Hospital, Kangbuk Samsung Hospital, 
and National Health Insurance Service Ilsan Hospital. This 
study included a total of 847 subjects who were diagnosed with 
T2DM and simultaneously evaluated using TE. Patients were 
defined as having T2DM if they met at least one of the follow-
ing criteria: (1) use of oral hypoglycemic agent or insulin; (2) 
previous diagnosis by a physician; (3) glycated hemoglobin 
(HbA1c) level of ≥6.5%; and (4) fasting plasma glucose con-
centration of ≥126 mg/dL [11]. The presence of NAFLD was 
defined as a controlled attenuation parameter (CAP) of ≥238 
dB/m or steatosis stage 1 (S1) on TE [12]. Of the 847 patients, 
149 were excluded based on the following exclusion criteria: (1) 
excessive alcohol consumption (≥210 g/week for males and 
≥140 g/week for females) (n=94) [3]; (2) hepatitis B or hepati-
tis C infection (n=37); (3) increased total and direct bilirubin 
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concentrations (n=16); and (4) missing anthropometric mea-
surements (n=2). A total of 698 participants with T2DM were 
enrolled in the final analysis.
The study protocol was approved by the Institutional Review 
Board of the Yonsei University College of Medicine, Seoul, Re-
public of Korea (approval no. 4-2018-0927). 
Laboratory assessment and data collection
Each patient underwent anthropometry, laboratory tests, TE, 
and questionnaire assessments. We obtained demographic and 
anthropometric data including age, sex, height, weight, and 
waist circumference and calculated body mass index (BMI) by 
dividing the body weight by the height squared (kg/m2). Blood 
pressure was measured using standard methods, and data con-
cerning personal medical history, current medication, and habit-
ual lifestyle factors, such as alcohol consumption, smoking sta-
tus, and physical activity, were collected via questionnaires. 
Blood samples were collected the morning after an 8-hour over-
night fast. Hypertension was defined as the current use of anti-
hypertensive medications or previous diagnosis by a clinical 
physician. We defined dyslipidemia as the use of a cholesterol-
lowering agent at the time of study enrollment or previous diag-
nosis by a health care professional. Alcohol intake was self-re-
ported by questionnaires inquiring about the frequency of drink-
ing, amount of alcohol consumed per drinking event, and types 
of beverages and quantified by calculating the daily alcohol 
consumption [10]. After excluding heavy drinkers according to 
the exclusion criteria, we categorized drinking status as non-
drinkers or current drinkers. Current drinker is defined as a per-
son who drinks at least once a week. Smoking status was cate-
gorized according to lifelong cigarette exposure as current 
smokers or non-current smokers, which included never smokers 
and past smokers. Physical activity was also self-reported, in-
cluding exercise frequency, duration, and intensity. Regular ex-
ercisers were defined as those patients who exercised for at least 
30 minutes twice per week or more.
Measurements of hepatic steatosis and fibrosis by TE
TE was recently accepted as a noninvasive and reliable tool for 
measuring liver steatosis and fibrosis. The CAP, a novel method 
for assessing hepatic steatosis, is based on the ultrasonic proper-
ties of attenuation obtained at 3.5 MHz using a FibroScan® de-
vice (Echosens, Paris, France) [12]. The basic principle of this 
noninvasive medical tool based on ultrasound attenuation has 
been described previously [12]. In addition, Fraquelli et al. [13] 
reported an excellent reproducibility of TE, and the intraclass 
correlation coefficients of both intraobserver and interobserver 
agreement were 0.98 for assessing hepatic fibrosis. TE was per-
formed by well-trained technicians who were blinded to the pa-
tients’ clinical and biochemical information. Regular acquisition 
procedures were performed as previously described with the pa-
tient lying in the dorsal decubitus position with the right arm in 
maximal abduction and the tip of the probe placed perpendicular 
to the skin over the right lobe of the liver through the intercostal 
spaces [14]. The CAP was expressed as dB/m and categorized 
into four stages: (1) steatosis stage 0 (S0) <238 dB/m; (2) 238 
dB/m≤ steatosis stage 1 (S1) <260 dB/m; (3) 260 dB/m≤ ste-
atosis stage 2 (S2) <293 dB/m; and (4) steatosis stage 3 (S3) ≥
293 dB/m [12]. In this study, the presence of NAFLD was de-
fined as a CAP of ≥238 dB/m, i.e., steatosis stage 1 (S1) or 
greater than S1. Liver stiffness measurement (LSM) was as-
sessed simultaneously and presented in kilopascals (kPa). The 
stages of fibrosis were classified as (1) no or mild fibrosis (F 
0–1), <7.7 kPa; (2) significant fibrosis (F2), ≥7.7 kPa; (3) ad-
vanced fibrosis (F3), ≥8.5 kPa; and (4) cirrhosis (F4), ≥10.5 
kPa [15]. To ensure validity, at least 10 valid measurements were 
obtained for CAP/LSM, with interquartile ranges (IQRs) of CAP 
of <40 dB/m [16] and an IQR to median value ratio (IQR/M) of 
<30% and an LSM success rate of >60% were considered reli-
able [17].
Statistical analyses
Continuous variables with normal and non-normal distributions 
are expressed as mean±standard deviation and median with 
IQR, respectively. Categorical variables are presented as fre-
quencies and percentages. Independent sample t tests and 
Mann–Whitney tests were used to compare continuous vari-
ables, while chi-square tests were used to compare categorical 
variables. Univariate logistic regression analyses were used to 
identify the potential predictors of NAFLD, with covariates with 
P<0.2 selected as candidate predictors [18]. Multivariable logis-
tic regression analyses with NAFLD as the endpoint were per-
formed to develop a new model. The backward selection method 
was applied from the initial model until we created final models 
with statistically significant covariates. The Hosmer-Lemeshow 
goodness-of-fit test was used to evaluate the model’s fitness. Ar-
eas under the receiver operating characteristic curves (AUROCs) 
with 95% confidence intervals (CIs) were used to assess the 
model’s performance, and the Youden index was used to deter-
mine effective cutoff values. The probabilities acquired from the 
final models were multiplied by 100 to obtain the scores. 
We then compared our new models with previously devel-
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oped NAFLD screening models using development datasets. 
The established screening methods included the fatty liver index 
[19] from an Italian cohort and the hepatic steatosis index [20] 
and Park’s index [21] from Korean cohorts. The sensitivity, 
specificity, positive predictive value (PPV), negative predictive 
value (NPV), positive likelihood ratio (LR+), negative likeli-
hood ratio (LR–), and area under the curve were calculated [10]. 
The Jonckheere-Terpstra test was used to determine the signifi-
cance of the trend. Statistical analyses were performed using 
SPSS Statistics for Windows version 25.0 (IBM Corp., Armonk, 
NY, USA) and R version 4.0.3 (R Foundation for Statistical 
Computing, Vienna, Austria). Statistical significance was set at 
P<0.05.
RESULTS
Baseline characteristics of the study population
Table 1 summarizes the characteristics of the study population 
according to NAFLD status. A total of 698 patients (445 men, 
253 women) with a mean age of 59.4±9.6 years were enrolled 
in the study. Fatty liver determined using TE was present in 
64.6% (n=451) of the total patients. The patients in the NAFLD 
group were younger than those in the non-NAFLD group (P=  
0.006). The percentage of males was higher than females in the 
NAFLD and non-NAFLD groups without a significant inter-
group difference in sex distribution. The mean BMI, waist cir-
cumference, and systolic and diastolic blood pressures were 







Age, yr 59.4±9.6 60.8±8.7 58.7±10.0 0.006a
Male sex 445 (63.8) 158 (64) 287 (63.6) 0.931
BMI, kg/m2 25.1±3.3 23.2±2.8 26.1±3.1 <0.001a
Waist circumference, cm 85.9±9.6 80.6±8.4 88.9±8.9 <0.001a
SBP, mm Hg 126.2±15 122.7±15.3 128.1±14.6 <0.001a
DBP, mm Hg 79.8±10.3 77.6±9.7 80.9±10.4 <0.001a
Hypertension 363 (52) 114 (46.2) 249 (55.2) 0.002a
Dyslipidemia 358 (51.3) 120 (48.6) 238 (52.8) 0.106
Regular exercise 496 (71.1) 196 (79.4) 300 (66.5) 0.010a
Current smoker 113 (16.2) 33 (13.4) 80 (17.7) 0.105
Current drinkerb 306 (43.8) 115 (46.6) 191 (42.4) 0.431
Fasting glucose, mg/dL 133.7±39.2 127.1±39.3 137.3±38.8 0.001a
HbA1c, % 7.1±1.4 6.9±1.3 7.2±1.4 <0.001a
Uric acid, mg/dL 5.2±1.4 5±1.3 5.3± 1.4 0.065
Total cholesterol, mg/dL 174.6±40.2 174.7±42.1 174.6±39.3 0.972
Triglyceride, mg/dL 109.5 (76–151) 91 (64–124) 121 (88–164.5) <0.001a
HDL-C, mg/dL 46 (39–54) 48 (41–61) 44.5 (39–52) <0.001a
LDL-C, mg/dL 105.6±36 102.8±37.4 107.2±35.2 0.127
AST, IU/L 29 (23–37) 26 (22–34) 30 (24–40) <0.001a
ALT, IU/L 29.5 (22–42.3) 25 (19–34) 33 (24–48) <0.001a
GGT, IU/L 28 (19–45) 21 (16–35) 31 (22–51.8) <0.001a
CAP, dB/m 254 (224–291) 212 (196–228) 280 (256–306) <0.001a
LSM, kPa 4.3 (3.5–4.9) 3.7 (3.3–4.4) 4.4 (3.8–5.2) <0.001a
Values are expressed as mean±standard deviation, number (%), or median (interquartile range).
NAFLD, nonalcoholic fatty liver disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated hemo-
globin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; GGT, gamma-glutamyl transferase; CAP, controlled attenuation parameter; LSM, liver stiffness measurement.
aStatistically significant values (P<0.05); bCurrent drinker is defined as a person who drinks at least once a week. However, we excluded patients with 
excessive alcohol intake with following criteria; ≥210 g/week for males and ≥140 g/week for females. 
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higher in the NAFLD group than in the non-NAFLD group, in-
dicating that patients with NAFLD were more likely to be obese 
and have hypertension (all P<0.05). Patients in the NAFLD 
group exercised less than those in the non-NAFLD group. Gly-
cemic parameters, including fasting glucose and HbA1c levels, 
were significantly higher in the NAFLD group. In addition, tri-
glyceride levels were higher and high-density lipoprotein cho-
lesterol (HDL-C) levels were lower in the NAFLD group than 
in the non-NAFLD group (all P<0.05). Regarding liver-associ-
ated parameters, AST, ALT, gamma-glutamyl transferase (γ-GT), 
and hepatic steatosis (CAP) and stiffness by TE in the NAFLD 
group were significantly higher than in the non-NAFLD group 
(P<0.001).
Development of non-laboratory and comprehensive 
models for NAFLD
Potential predictors of NAFLD were analyzed using a simple 
logistic regression model. Variables were selected based on 
clinical judgment and reported risk factors for NAFLD [22] and 
statistical significance in the current study. Age, waist circum-
ference, BMI, dyslipidemia, hypertension, physical activity, 
smoking status, fasting glucose, HbA1c, triglyceride, HDL-C, 
low-density lipoprotein cholesterol, ALT/AST ratio, and γ-GT 
were chosen as candidate predictors of NAFLD in the univari-
ate logistic regression model (P<0.2) (Supplemental Table S1). 
We also included sex among the candidate predictors according 
to the clinical judgment [23]. Multivariable logistic regression 
analyses with backward selection method were performed to 
derive the final model. Table 2 presents the final non-laboratory 
and comprehensive model. Non-laboratory parameters, such as 
anthropometric data or variables obtained through inquiries, 
were used in the development of a simple non-laboratory mod-
el. This model comprised six variables, including age, sex, waist 
circumference, BMI, dyslipidemia, and smoking status, and fit-
ted well (P=0.199, Hosmer-Lemeshow statistics) with AU-
ROCs of 0.780 (95% CI, 0.743 to 0.817) (Fig. 1A). We multi-
plied the probabilities resulting from the non-laboratory model 
by 100 to obtain scores ranging from 0 to 100, and the probabil-
ity of having NAFLD was calculated as follows: 
The non-laboratory model score, probability (%) of having 
NAFLD=1/(1+exp(–x))×100.
x=–10.572+(–1.853)×(1 if age ≥40 years, 0 if age <40 
years)+1.027×sex (female=1, male=0)+0.112×waist+0.12×
BMI+0.227×dyslipidemia (yes=1, no=0)+0.414×smoking 
status (current smoker=1, non-current smoker=0)
These scores can be interpreted as the average probability of 
NAFLD in T2DM patients.
Serum biomarkers were included in the development of the 
comprehensive model. Seven variables—age, sex, waist cir-
cumference, BMI, HbA1c, triglyceride, and ALT/AST ratio—
were identified as significant predictors of NAFLD, and the 
comprehensive model also fitted well (P=0.243, Hosmer-Lem-
eshow statistics). The comprehensive model showed an im-
proved discrimination ability compared to the non-laboratory 
model, with an AUROC of 0.815 (95% CI, 0.782 to 0.847) (Fig. 
1B). We also multiplied the probabilities resulting from the 
comprehensive model by 100 to obtain an index score ranging 
from 0 to 100. The probability of having NAFLD in the com-
prehensive model is calculated as follows:
The comprehensive model score, probability (%) of having 
Table 2. The Parameters of Predictors of NAFLD in Simple 







Age, yr - 0.982 (0.960–1.004)
   <40 1.0 (reference) -
   ≥40 0.157 (0.018−1.357) -
Sex
   Male   1.0 (reference) 1.0 (reference)
   Female 2.791 (1.715−4.544) 3.370 (2.070–5.486)
Waist circumference, cm 1.118 (1.069−1.170) 1.115 (1.062–1.169)
BMI, kg/m2 1.128 (0.996−1.277) 1.122 (0.986–1.276)
Dyslipidemia 1.255 (0.868−1.814) -
Current smoking 1.513 (0.905−2.530) -
HbA1c, % - 1.120 (0.967–1.297)
TG, mg/dL - 1.005 (1.001–1.008)
ALT/AST ratio - 4.342 (2.218–8.501)
AUC 0.780 0.815
Nagelkerke R2 0.304 0.381
Multivariable logistic regression analysis was performed. 
The screening index of non-laboratory model=1/(1+exp (–x))×100; 
x=–10.572+(–1.853)×(1 if age ≥40, 0 if age <40)+1.027×sex (fe-
male=1, male=0)+0.112×waist+0.12×BMI+0.227×dyslipidemia 
(yes=1, no=0)+0.414×smoking status (current smoker=1, non-current 
smoker=0); The screening index of comprehensive model=1/(1+exp 
(–x))×100; x=–13.606+(–0.018)×age+1.215×sex (female=1, 
male=0)+0.109×waist+0.115×BMI+0.113×HbA1c+0.005×TG+ 
1.468×ALT/AST.
NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; CI, confi-
dence interval; BMI, body mass index; HbA1c, glycated hemoglobin 
A1c; TG, triglyceride; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; AUC, area under the curve.
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NAFLD=1/(1+exp(–x))×100.
x=–13.606+(–0.018)×age+1.215×sex (female=1, male=  
0)+0.109×waist+0.115×BMI+0.113×HbA1c+0.005×triglyc-
eride+1.468×ALT/AST
Comparison with existing NAFLD screening models
We compared the predictive power of our new screening indices 
with those of previously developed models, such as the hepatic 
steatosis index [20], Park’s index [21], and fatty liver index [19], 
using our development dataset (Table 3). In the non-laboratory 
model, an index score of ≥60 was set as the cutoff value, as it 
provided the highest Youden index with a sensitivity of 74%, 
specificity of 69%, PPV of 80%, and NPV of 61%. The compre-
hensive model showed a high risk of developing NAFLD for a 
cutoff score of ≥62, which also provided the maximal Youden 
index. The comprehensive model showed a sensitivity of 75% 
and specificity of 73% for an index score of ≥62. The sensitivity, 
specificity, PPV, NPV, LR+, LR–, and AUROCs of previously 
established screening models were analyzed using our develop-
ment dataset. Our simple non-laboratory model was not inferior 
to other established models, including laboratory parameters. 
Moreover, the comprehensive model showed a numerically high-
er predictability for NAFLD than previous prediction models.
Fig. 2 shows the prevalence of NAFLD in both sexes accord-
ing to score categories based on non-laboratory and comprehen-
sive screening scores. The prevalence of NAFLD increased 
with increasing screening scores. Fatty liver grades assessed by 
TE showed significant associations with the new screening 
scores in simple linear regression models (R2=0.249 and R2=  
0.332 in the non-laboratory and comprehensive models, respec-
tively, P<0.001) (Supplemental Table S2). The screening scores 
increased with steatosis grade, suggesting that the new scores 
reflected the degree of fatty liver (Supplemental Fig. S1).
DISCUSSION
The worldwide distribution and increasing prevalence of 
NAFLD parallels the frequencies of obesity and unhealthy life-
styles, including in Asian countries [1,24]. Sedentary lifestyles 
and the prevalence of obesity have been constantly increasing in 
recent decades in Korea, contributing to the high prevalence of 
NAFLD [4,25,26]. Despite the increasing high-risk population 
of NAFLD, more than 95% of people with suspected NAFLD 
are unaware that they have liver disease [27]. Thus, many pa-
tients with NAFLD lack proper medical treatment, leading to 
liver-related and overall mortality. Due to its close association 
with cardiometabolic diseases, cancers, and end-stage liver dis-
ease [3], NAFLD accounts for a large part of public health ex-
penses [28]. The diagnosis and treatment of NAFLD may en-
hance public health and reduce public health costs.
T2DM is a major risk factor for NAFLD [2]. The incidence of 































 20 40 60 80 100  20 40 60 80 100
Fig. 1. (A) Receiver-operating characteristic (ROC) curve of non-laboratory screening model for the prediction of nonalcoholic fatty liver 
disease. The area under ROC curve (AUC) is 0.780 (95% confidence interval [CI], 0.743 to 0.817). At cutoff value of 60, sensitivity is 74%, 
specificity is 69%, respectively. (B) ROC curve of comprehensive screening model for the prediction of nonalcoholic fatty liver disease. The 
AUC is 0.815 (95% CI, 0.782 to 0.847). At cutoff value of 62, sensitivity is 75%, specificity is 73%, respectively.
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patients with NAFLD and concomitant diabetes than in those 
with NAFLD but without diabetes [29]. The 2016 European As-
sociation for the Study of the Liver (EASL), European Associa-
tion for the Study of Diabetes (EASD) and European Associa-
tion for the Study of Obesity (EASO) Clinical Practice Guide-
lines for the management of NAFLD also recommend cautious 
examinations for the presence of NAFLD in patients with 
T2DM regardless of liver enzyme levels [3]. Thus, developing 
an effective modality for the early screening of NAFLD is espe-
cially crucial for patients with T2DM who have a higher risk and 
worse prognosis of NAFLD compared to the general population.
Various screening methods have been adopted to detect 
NAFLD, including ultrasonography, TE, CT, and MRI. Never-
theless, there are many practical restrictions in the clinical set-
ting in terms of the cost-effectiveness of performing imaging 
studies for NAFLD screening in all patients with T2DM. There-
fore, we established non-laboratory and comprehensive models 
as a noninvasive and easy screening tool for NAFLD among 
patients with T2DM to identify individuals who require further 
evaluation and therapeutic interventions.
The results of the current study are consistent with those re-
ported previously. NAFLD was highly prevalent in the present 
study, similar to previous observations [5]. Moreover, we also 
observed a close relationship between NAFLD and obesity oth-
er than alcohol consumption as reported previously [22,30]. In 
our prediction model, BMI and waist circumference, which rep-


















   Non-laboratory model ≥60 58 74 69 80 61 2.41 0.37 43 0.780
   Comprehensive model ≥62 58 75 73 83 62 2.77 0.34 48 0.815
Internal validation (n=698)
   Hepatic steatosis index 51 65 74 82 53 2.49 0.48 41 0.779
   Park’s index 56 71 69 80 57 2.26 0.43 39 0.761
   Fatty liver index 19 27 95 90 42 5.13 0.77 44 0.777
Hepatic steatosis index (HSI)=8×ALT/AST ratio+BMI (+2, if diabetes; +2, if female), cutoff value of HSI >36 for high-risk or <30 for no NAFLD; 
Park’s index=(ALT/AST ratio >1.5)×1+(γ-glutamyl-transferase >50)×1+(triglycerides >150)×1+(23≤ BMI <25)×2+(25≤ BMI)×3, cutoff value 
of Park’s index ≥3; Fatty liver index (FLI)=1/(1+exp(–x))×100, x=0.953×loge (TG)+0.139×BMI+0.718×loge (γ-glutamyl-transferase)+0.053×
WC–15.745, cutoff value of FLI ≥60 for high-risk or <30 for no NAFLD.
NAFLD, nonalcoholic fatty liver disease; PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio; AUC, area under the 





































Non-laboratory score Comprehensive score
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Fig. 2. Prevalence of nonalcoholic fatty liver according to score categories of screening models in development dataset. (A) Non-laboratory 
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resent overall and central obesity, respectively, were important 
predictors of NAFLD and supported the tight association be-
tween fat accumulation and NAFLD [30]. Meanwhile, our 
models showed no association between the risk of NAFLD and 
alcohol consumption.
Our new prediction models differ from previous models in 
several ways. Most previous prediction models were developed 
for the general population and involved only the presence or ab-
sence of diabetes rather than the degree of glycemic control 
[20,31,32]. Our study confirmed the predictive power of the 
comprehensive model according to the degree of glycemic con-
trol in patients with T2DM. Our data indicate that clinicians 
should be aware of strict glycemic control to prevent the devel-
opment of NAFLD. Unlike previously established NAFLD pre-
diction models [10,31], our models do not show an increased 
risk of NAFLD with age. This finding is also supported by the 
study by Bedogni et al. [22] showing that NAFLD is not sys-
tematically associated with age. Younger patients in our devel-
opment dataset tended to have a higher BMI and waist circum-
ference, suggesting that younger adults were more obese (Sup-
plemental Figs. S2, S3). According to the Korea National Health 
and Nutrition and Examination Survey (KNHANES) 2019, the 
prevalence of obesity was the highest among individuals in their 
60s (37.3%), followed by those in their 50s (36.5%) and 40s 
(35.6%) [33], suggesting that more obese people are relatively 
younger. As fat accumulation is one of the major risk factors of 
NAFLD [2,3], this metabolic characteristic of young patients 
could explain the trend of the reverse relationship between age 
and NAFLD in the current prediction model. Our data also im-
plied that fat accumulation may play a more important role than 
aging in the development of NAFLD.
There are conflicting views regarding the influence of sex on 
NAFLD. While some studies have described male predomi-
nance in NAFLD [24], others suggest a higher prevalence in 
women [34]. Other studies have not found an association be-
tween NAFLD and sex [22]. In the present study, female sex 
was identified as a risk factor for NAFLD. Like other chronic 
liver diseases, NAFLD is also influenced by the hormonal sta-
tus. Although many studies demonstrated a higher prevalence of 
NAFLD in men than that in women, after menopause, the prev-
alence of NAFLD in women exceeded that of men [35-37]. Es-
trogen has protective effects against liver injury and reduce he-
patic fibrosis progression in animal models [38]. While female 
sex hormones protect against hepatic steatosis in premenopausal 
women, this effect disappears after menopause. Unfavorable 
physiological changes occur in postmenopausal women, includ-
ing fat redistribution and metabolic changes, such as increased 
insulin resistance, resulting in the development of NAFLD [39]. 
Unfortunately, information on menopausal status was not avail-
able for our dataset. However, considering that the mean age of 
the female participants in the study was 60.8±9.9 years (Sup-
plemental Table S3) and the mean age at natural menopause in 
Korean women is 49.3 years [40], most of the female partici-
pants in our dataset were presumed to be postmenopausal. Thus, 
the increased age with possible postmenopausal status in female 
patients might have affected the high odds ratio of NAFLD in 
women in the current study.
An increase in γ-GT is among the most common biochemical 
abnormalities in NAFLD, and γ-GT was included in the previ-
ous NAFLD prediction models [19,41]. However, γ-GT did not 
show statistical significance in our comprehensive model. The 
mitigated predictive power of γ-GT for NAFLD in the current 
study is probably due to the relatively early stages of NAFLD 
among the study population. Since γ-GT is an antioxidant that 
provides cellular defense in many cells, including hepatocytes 
[42], it is further increased with NAFLD progression [43]. Ac-
cording to a previous study [44], 23 of 102 individuals with 
normal liver findings on ultrasonography were diagnosed with 
NAFLD on TE, suggesting that TE is more sensitive than ultra-
sonography at detecting mild steatosis. Considering that previ-
ous NAFLD prediction models used ultrasonography [19], rela-
tively advanced stages of NAFLD with sufficiently increased 
γ-GT levels may have been diagnosed, leading to γ-GT as a sig-
nificant predictor of NAFLD. However, since the current study 
detected relatively early stages of hepatic steatosis using TE 
compared with previous studies using ultrasonography, γ-GT 
may not have increased enough to be a significant predictor of 
NAFLD. In addition, the median γ-GT value was 31 IU/L, even 
in patients with NAFLD (Table 1), which was lower than the 
recommended cutoff value for the upper normal limit of γ-GT 
(51 IU/L for men and 33 IU/L for women) [45]. This implies 
that the current study mainly consisted of patients with early 
stages of NAFLD in which γ-GT had not been sufficiently in-
creased to predict it. Furthermore, γ-GT can also be increased in 
other conditions of oxidative stress, such as alcohol-related dis-
eases, heart failure, chronic kidney disease, dementia, and 
T2DM, along with increased insulin resistance [42,45]. The fact 
that the non-NAFLD control group was composed of only pa-
tients with T2DM might have resulted in the increased level of 
γ-GT in the non-NAFLD control group [46]. Therefore, the in-
creased level of γ-GT in the non-NAFLD reference group may 
have reduced the difference in γ-GT levels between the NAFLD 
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and non-NAFLD groups, decreasing the predictive power of 
γ-GT for NAFLD.
The present study has clinical significance owing to its novel-
ty. First, pre-existing NAFLD prediction models were devel-
oped based on the diagnosis of NAFLD by ultrasonography or 
CT [10,19-21,31]. In contrast, we used TE as a diagnostic tool 
for NAFLD. Although ultrasonography is recommended as a 
first-line diagnostic imaging tool for NAFLD [3], TE is a prom-
ising device for simultaneously assessing liver fibrosis and ste-
atosis [12,15]. For measuring CAP, TE is faster, more reproduc-
ible, and less operator-dependent than ultrasonography [12,44]. 
TE also shows improved diagnostic performance compared 
with CT [47]. Hence, we considered our prediction model as 
based on reliable methods for detecting NAFLD.
The second strength of the current study was that new predic-
tive models were specifically developed in patients with T2DM. 
The pathophysiology of NAFLD in T2DM is distinct from that 
of NAFLD without diabetes. Glucotoxicity induced by persis-
tent hyperglycemia with resultant chronic inflammation is the 
key pathophysiology of NAFLD in T2DM [48]. Therefore, an 
independent prediction model for NAFLD in T2DM patients is 
needed. Furthermore, to our knowledge, this is the first study to 
suggest a non-laboratory parameter-based prediction model of 
NAFLD determined using a FibroScan in patients with T2DM. 
The model is self-assessable with user-friendly parameters, and 
it enables high-risk patients with T2DM to easily calculate their 
probabilities of having NAFLD.
Our study has limitations that could be further investigated in 
subsequent studies. First, the levels of postprandial metabolic 
parameters such as glucose, insulin, and C-peptide were not 
measured due to the nature of routine healthcare checkups, al-
though these parameters could be contributing factors for the 
prediction of NAFLD. For instance, a 1-hour postprandial glu-
cose level above 155 mg/dL during an oral glucose tolerance 
test was associated with an increased risk of NAFLD and close-
ly correlated with hepatic insulin resistance [49]. Hence, the in-
clusion of postprandial blood biomarkers in the NAFLD predic-
tion model may reflect the components of hepatic insulin resis-
tance in patients with T2DM. Therefore, further studies are 
needed to establish a more accurate prediction model of 
NAFLD that includes postprandial laboratory parameters. Sec-
ond, although it is the gold standard for diagnosing NAFLD, 
liver biopsy was not performed in the present study. However, 
although TE is not a perfect method for diagnosing NAFLD, it 
could be considered a useful noninvasive substitute for liver bi-
opsy considering its high diagnostic accuracy at detecting mild 
hepatic steatosis (sensitivity 87%, specificity 91%) [50]. Never-
theless, since there are some limitations of TE, further research 
is required to develop and validate NAFLD prediction models 
based on datasets from liver biopsy or MRI-based methods, 
which will provide excellent predictive power. Third, informa-
tion on menopausal status that might affect the risk of NAFLD 
[39] could not be confirmed in the present study. Fourth, as ex-
ternal validation was not performed in the current study, sys-
temic validation studies are warranted before the new prediction 
models can be utilized in clinical practice. 
In conclusion, we developed and suggested new screening 
methods for NAFLD specifically for use in patients with T2DM 
at higher risk of developing NAFLD than the general popula-
tion. The non-laboratory simple and comprehensive models 
were not inferior compared to existing models, and further in-
vestigations are needed to verify the efficacy and feasibility of 
these models in clinical practice. We hope that our new models 
will serve as noninvasive and cost-effective methods of screen-
ing for NAFLD in patients with T2DM.
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